ADAR1 Capital Management »

Surrozen shares owned by ADAR1 Capital Management

Quarter-by-quarter ownership of Surrozen (SRZN) shares owned by ADAR1 Capital Management from 13F filings

Historical chart of ADAR1 Capital Management investment in Surrozen

Tip: Access up to 7 years of quarterly data

All positions including Surrozen held by ADAR1 Capital Management consolidated in one spreadsheet with up to 7 years of data

Download as csvDownload consolidated filings csv Download as ExcelDownload consolidated filings xlsx

Quarterly reported holdings in Surrozen by ADAR1 Capital Management

Quarter filed Position value Share count Share price at filing
2024-03-31 $7.1k 450 15.71

More positions owned by ADAR1 Capital Management

Alnylam Pharmaceuticals (ALNY)
Ea Series Trust Alpha Arch 1-3 (BOXX)
Roivant Sciences SHS (ROIV)
Spdr S&p 500 Etf Tr Tr Unit Put Option (SPY)
Protagonist Therapeutics (PTGX)
Cytokinetics Com New (CYTK)
Keros Therapeutics (KROS)
Royalty Pharma Shs Class A (RPRX)
Bridgebio Pharma (BBIO)
Merrimack Pharmaceuticals In Com New (MACK)
Ascendis Pharma A/s Sponsored Adr (ASND)
Arbutus Biopharma (ABUS)
Avrobio Ord (AVRO)
Beigene Sponsored Adr (BGNE)
Invesco Qqq Tr Unit Ser 1 Put Option (QQQ)

View all positions for ADAR1 Capital Management

Top funds holding Surrozen

Euclidean Capital
Vanguard Group
Arrowpoint Asset Management
Board of Trustees of The Leland Stanford Junior University
Trustees of Columbia University in the City of New York
Morgan Stanley
Alyeska Investment Group
Renaissance Technologies
Geode Capital Management
BlackRock
ADAR1 Capital Management
Wolverine Asset Management
Tower Research Capital
Royal Bank of Canada
Wells Fargo & Company

View all funds holding Surrozen